This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Information about Porphyrias, Hepatic: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Most recent studies have shown that Porphyrias, Hepatic shares some biological mechanisms with abdominal-pain, acute-intermittent-porphyria, acute-interstitial-pneumonia, carcinoma, dermatologic-disorders, disorders-of-porphyrin-metabolism, drug-induced-liver-injury, erythropoietic-protoporphyria, hepatitis, hereditary-coproporphyria, liver-carcinoma, liver-cirrhosis, liver-diseases, metabolic-diseases, pain, porphobilinogen-synthase-deficiency, porphyria-cutanea-tarda, porphyria-erythropoietic, variegate-porphyria.
Among the many pathways, these few ones have gauged particular interests from scientists studying Porphyrias, Hepatic, and have been seen in publications frequently: Cell Activation, Cell Adhesion, Cell Maturation, Cell Proliferation, Complement Activation, Conjugation, Excretion, Gluconeogenesis, Inflammatory Response, Keratinization, Localization, Oxidative Phosphorylation, Oxygen Transport, Pathogenesis, Pigmentation, Secretion, Superoxide Anion Generation, Translation, Transport, Vasoconstriction
Quite a number of genes have been found to play important roles in Porphyrias, Hepatic, such as AHR, AIP, ALAD, ALAS1, AMBP, AURKAIP1, AVP, CPO, CPOX, CYP1A1, DDC, EPX, FECH, HCRT, HMBS, HRC, PPOX, PTPN6, TDO2, UROD. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.